

May 23, 2008

**APA DSM-V Work Group Member**

**Name, Degree:** James F. Leckman, M.D.

**Role(s) in Work Group:** Member, Disorders in Childhood and Adolescence Work Group

**Institutional Affiliation(s):** Yale University

**City, State:** New Haven, CT

**Biographical Sketch:**

James F. Leckman, M.D. is the Neison Harris Professor of Child Psychiatry, Psychiatry, Psychology and Pediatrics at Yale. He serves as the Director of Research for the Yale Child Study Center. Dr. Leckman is a well-known child psychiatrist and patient-oriented clinical investigator. His peers have regularly selected him as one of the Best Doctors in America. Dr. Leckman is the author or co-author of over 300 original articles published in peer-reviewed journals, seven books, and 120 book chapters. In 2002, he was identified by American Society for Information, Science and Technology as a "Highly Cited Researcher" - one of the world's most cited authors in Psychology and Psychiatry – in the top half of the top one percent of all publishing researchers.

In 1999, he edited with Dr. Donald J. Cohen, Tourette's Syndrome: Tics, Obsessions, Compulsions - Developmental Psychopathology and Clinical Care, published by John Wiley & Sons. Given its success, this volume was re-issued in paper back in the fall of 2001. More recently, Dr. Leckman edited a 56-chapter volume, entitled, Pediatric Psychopharmacology: Principles and Practice published in October of 2002 by Oxford University Press. In November 2002, an invited review article on Tourette's syndrome appeared in the prestigious medical journal The Lancet.

Dr. Leckman is widely recognized as a committed clinician with special skills in the evaluation and treatment of Tourette's syndrome and early onset obsessive-compulsive disorder. Since the early 1980s, he has seen and evaluated hundreds of individuals with these conditions. Physicians, patients and families from across the country and around the world regularly seek his advice. He is frequently invited to address professional, parent and advocacy groups at local, regional, and national meetings as well as international meetings. For example during the past four years, he has presented to professional and/or family groups in London, Rotterdam, Berlin, Rome, Johannesburg, Istanbul, Beirut, Sharm El Sheikh, Tehran, Tel Aviv, Taipei, Tokyo, Mexico City, Lima, and Sao Paulo. He is also a fully trained psychoanalyst.

**UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V: CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.**

<b>Non-Profit and Advocacy Organizations</b>	<b>Year(s)</b>	<b>Role</b>
NARSAD	2005-2008	Scientific Advisor
NORD	2005-2008	Scientific Advisor
Tourette Syndrome Association	2005-2008	Scientific Advisor

The two tables below represent Dr. Leckman's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Leckman has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p><b>KEY NUMBER:</b></p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

**DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
McGraw Hill	2005-2007	7
Oxford Press	2005-2007	7
Wiley & Sons	2005-2007	7

**DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
McGraw Hill	2008	7
Oxford Press	2008	7
Wiley & Sons	2008	7